Japanese companies may present applications in person:
This article was originally published in Clinica
Executive Summary
Japanese companies filing for product approvals are to be permitted to present their products and associated data to the licensing authorities in person, under a new move designed to curtail the sometimes lengthy approval process. Questions and answers on a product may flow to and fro between authority and applicant, the licensing authorities sometimes needing explicit explanations on new technologies. The person-to-person approach may offer a short cut, with each company able to present for 30 minutes and then be expected to respond to questions for a similar length of time. Prefectural governments were informed of the new application filing method in March.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.